Molecular Docking Study of Novel Nitrofuran Derivatives As Urinary Tract Anti Infectives
DOI:
https://doi.org/10.22270/ajprd.v10i5.1178Keywords:
Rosella flower, extract, gel, disclosing solutionAbstract
Modern drug design commonly uses molecular docking to understand drug-receptor interaction. For docking tests against 1YLU, an E. coli nitro-reductase, substituted furan derivatives were used in the current work. The study's primary goal is to dock the chosen nitrofuran derivatives onto the protein and compare the results to those of nitrofurantoin as a standard drug. PyRx and the discovery studio visualizer (DSV) application were used to carry out the molecular docking analysis, and E. coli nitro-reductase (1YLU) was retrieved from the protein data bank (PDB) website. All seven of the nitrofuran compounds docking scores were discovered to range between -5.9 and -8.8 Kcal/mol. Compound 2a received the highest binding score, with a score of -8.80 Kcal/mol.At the protein active site, compound 2a interacts with amino acids such as glutamic acid (GLU 165), arginine (ARG 10 & 207), serine (SER 39 & 12), glutamine (GLN 142), and lysine (LYS205).Numerous nitrofuran substituted compounds have been identified for the activity and the nitrofuran derivatives have been discovered to exhibit urinary tract anti-infective activities.
Downloads
References
2. Richards WA, Riss E, KASS EH, FINLAND M. Nitrofurantoin: clinical and laboratory studies in urinary tract infections. AMA Archives of Internal Medicine. 1955 Oct 1;96(4):437-50.
3. Dodd MC, Cramer DL, Ward WC. The relationship of structure and antibacterial activity in the nitrofurans. Journal of the American Pharmaceutical Association (Scientific ed.). 1950 Jun 1;39(6):313-8.
4. El-Wakil MH, Meheissen MA, Abu-Serie MM. Nitrofurazone repurposing towards design and synthesis of novel apoptotic-dependent anticancer and antimicrobial agents: Biological evaluation, kinetic studies and molecular modeling. Bioorganic Chemistry. 2021 Aug 1;113:104971.
5. Elsaman T, Mohamed MS, Mohamed MA. Current development of 5-nitrofuran-2-yl derivatives as antitubercular agents. Bioorganic Chemistry. 2019 Jul 1;88:102969.
6. Zuma NH, Smit FJ, Seldon R, Aucamp J, Jordaan A, Warner DF, David DD. Single-step synthesis and in vitro anti-mycobacterial activity of novel nitrofurantoin analogues. Bioorganic chemistry. 2020 Mar 1;96:103587.
7. Zorzi RR, Jorge SD, Palace-Berl F, Pasqualoto KF, de Sá Bortolozzo L, de Castro Siqueira AM, Tavares LC. Exploring 5-nitrofuran derivatives against nosocomial pathogens: synthesis, antimicrobial activity and chemometric analysis. Bioorganic & medicinal chemistry. 2014 May 15;22(10):2844-54.
8. Zuma NH, Aucamp J, David DD. An update on derivatization and repurposing of clinical nitrofuran drugs. European Journal of Pharmaceutical Sciences. 2019 Dec 1; 140:105092.
9. Basil Britto Xavier, Jascha Vervoort, Andrew Stewardson, Surbhi Malhotra kumar.Complete Genome Sequence of nitrofurantoin-Sensitive and -Resistant Escherichia coli ST540 and ST2747 Strains: Journals.ASM.org 2014April 2(2); e00239-14
10. Germeau F, Van Regemorter G. Prolonged-action nifurtoinol in urinary infections. Comparative study. Acta urologica Belgica. 1983;51(3):373-8.
11. Paudel S, John PP, Poorbaghi SL, Randis TM, Kulkarni R. Systematic Review of Literature Examining Bacterial Urinary Tract Infections in Diabetes. Journal of Diabetes Research. 2022 May 17;2022.
12. Ohyama A. On the antibacterial action and mechanism of nitrofuran derivatives. Bulletin of the Institute for Chemical Research, Kyoto University. 1956 Mar 30;34(1-2):25-55.
13. Stewart BL, Rowe HJ. Nitrofurantoin (furadantin) in treatment of urinary tract infections. Journal of the American Medical Association. 1956 Apr 7;160(14):1221-3.
14. Lippman RW, Wrobel CJ, Rees R, Hoyt R. A theory concerning recurrence of urinary infection: prolonged administration of nitrofurantoin for prevention. The Journal of Urology. 1958 Jul;80(1):77-81.
15. Marshall M, Johnson SH. An initial report of the treatment of chronic urinary tract infection in children with nitrofurantoin. The Journal of Urology. 1956 Jul;76(1):123-8.
16. Kalowski S, Radford N, Kincaid-Smith P. Crystalline and macrocrystalline nitrofurantoin in the treatment of urinary tract infection. New England Journal of Medicine. 1974 Feb 14;290(7):385-7.
17. Main RJ. The nitrofurans-a new type of antibacterial agent. Journal of the American Pharmaceutical Association. 1947 Oct;36(10):317-20.
Published
How to Cite
Issue
Section
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.